Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534267 | 1.00 | FFAR1 (0.46) | FFAR1PPARGALDH1A1MAPTSMYD2 | |
| SCHEMBL25906381 | 0.80 | CHRNB2 (0.50) | — | |
| SCHEMBL22554967 | 0.78 | SMYD2 (0.39) | SMYD2 | |
| SCHEMBL22554969 | 0.78 | SMYD2 (0.39) | SMYD2 | |
| SCHEMBL29945202 | 0.78 | CHRNB4 (0.43) | — | |
| SCHEMBL29875863 | 0.78 | CHRNB4 (0.43) | — | |
| SCHEMBL31460034 | 0.75 | SMYD2 (0.38) | ALDH1A1SMYD2 | |
| SCHEMBL12082307 | 0.74 | FFAR1 (0.56) | FFAR1PPARGMAPT | |
| SCHEMBL12082229 | 0.74 | FFAR1 (0.56) | FFAR1PPARGMAPT | |
| SCHEMBL23665772 | 0.74 | CASP3 (0.36) | SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180298030-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | Université de Montréal (CA) | 2018-10-18 | — | — | US | disclosed |
| WO-2017066863-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | FFAR1 1161/4885PPARG 2620/4885ALDH1A1 1559/4885 |
| US-20180298030-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | F12, F2, F3 | FFAR1 1161/4885PPARG 2620/4885ALDH1A1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.